Provided by Tiger Trade Technology Pte. Ltd.

Altimmune, Inc.

2.80
-0.0500-1.75%
Post-market: 2.800.00000.00%19:56 EDT
Volume:5.89M
Turnover:16.51M
Market Cap:543.20M
PE:-2.80
High:2.91
Open:2.86
Low:2.75
Close:2.85
52wk High:7.73
52wk Low:2.75
Shares:194.00M
Float Shares:186.00M
Volume Ratio:0.55
T/O Rate:3.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9999
EPS(LYR):-0.9999
ROE:-50.57%
ROA:-28.17%
PB:2.42
PE(LYR):-2.80

Loading ...

Altimmune closes USD 225 million follow-on stock offering with warrants

Reuters
·
Yesterday

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

THOMSON REUTERS
·
Yesterday

Altimmune Inc: Financing Funds Operations Through Anticipated Phase 3 Mash 52-Week Data Readout

THOMSON REUTERS
·
Yesterday

Altimmune Inc: Intends to Use Net Proceeds to Fund Its Upcoming Phase 3 Trial in Mash, Expects to Initiate Its Phase 3 Trial in Mash in H2

THOMSON REUTERS
·
Yesterday

Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026

prnewswire
·
Apr 26

Altimmune upgraded to Neutral from Sell at Goldman Sachs

TIPRANKS
·
Apr 24

BUZZ-U.S. STOCKS ON THE MOVE- Lululemon, United Rentals, cannabis stocks

Reuters
·
Apr 24

Altimmune Shares Drop After $225 Million Offering Prices

Dow Jones
·
Apr 23

ALT Resources Advances Tartana Reverse Takeover and Secures £208,750 Funding

TIPRANKS
·
Apr 23

Altimmune prices oversubscribed USD 225 million public offering with warrants

Reuters
·
Apr 23

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

THOMSON REUTERS
·
Apr 23

BRIEF-Altimmune Announces Proposed Underwritten Public Offering Of Securities

Reuters
·
Apr 23

Altimmune launches underwritten public offering with common stock, warrants

Reuters
·
Apr 23

Altimmune Announces Proposed Underwritten Public Offering of Securities

THOMSON REUTERS
·
Apr 23

Altimmune Inc - Net Proceeds to Fund Phase 3 Mash Trial and General Purposes

THOMSON REUTERS
·
Apr 23

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

GlobeNewswire
·
Apr 22

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

GlobeNewswire
·
Apr 20

Altimmune shareholders approved increase in authorized common shares to 400 million

Reuters
·
Apr 17

Press Release: Harrow Announces the Issuance of J-Code for IOPIDINE(R) 1%

Dow Jones
·
Apr 16

Altimmune Insider Makes Bold New Share Grab

TIPRANKS
·
Apr 07